Detailed Narrative
GARDASIL China Re-evaluation and Strategic Pause
Merck has temporarily paused shipments of GARDASIL to China from February through at least midyear 2025 due to challenging market dynamics, elevated channel inventory, and soft consumer spending. This decision aims to accelerate inventory reduction and support the financial position of commercialization partner Zhifei. While the long-term $11 billion sales target for GARDASIL has been withdrawn due to uncertain timing of📎 economic recovery in China, Merck remains committed to maximizing the significant long-term opportunity in the region, especially with the recent male indication approval.
WINREVAIR Clinical and Commercial Momentum
WINREVAIR, the first and only activin signaling inhibitor for pulmonary arterial hypertension (PAH), demonstrated overwhelming efficacy in the Phase III ZENITH trial, leading to its early stoppage. The HYPERION study was also stopped early due to loss of clinical equipoise. Commercial launch is progressing well, with $200 million in Q4 sales, approximately 5,200 new patients prescribed since launch, and strong access. Initial international launches are also performing positively, reinforcing confidence in its growth expectations.
Diversified Pipeline for Long-Term Growth
Merck has significantly diversified its pipeline, nearly tripling late-phase assets over the past three years across oncology, cardiometabolic, immunology, HIV, ophthalmology, infectious disease, and vaccines. These programs represent over $50 billion in potential revenue opportunity, with 20 potential new growth drivers identified, almost all having blockbuster potential. This diversification is key to navigating the KEYTRUDA LOE period and sustaining long-term value creation.
Oncology Pipeline Expansion
The oncology pipeline continues to deepen beyond KEYTRUDA, with significant progress in antibody-drug conjugates (ADCs) from Kelun and Daiichi Sankyo, small molecule targeted therapies, and the individualized neoantigen therapy (INT) partnership with Moderna. The recent addition of a T-cell engager from Harpoon and a PD-1/VEGF bispecific antibody from LaNova further enhances the portfolio. Subcutaneous pembrolizumab is also expected to be filed and potentially launched in 2025.
Cardiometabolic and Infectious Disease Progress
In cardiometabolic, Merck anticipates Phase III readouts for its oral PCSK9 inhibitor, enlicitide, in April, July, and August 2025, aiming to achieve similar efficacy to antibody PCSK9 inhibitors. A licensing agreement for an oral GLP-1 receptor agonist (MK-4082) with Hansoh Pharma further strengthens this area. In infectious diseases, the FDA has set a June 10 target action date for clesrovimab, a long-acting monoclonal antibody for RSV in infants, and positive Phase III results for islatravir-based regimens in HIV were announced.
Capital Allocation and Shareholder Returns
Merck's capital allocation strategy prioritizes investments in the business and pipeline, maintaining a commitment to increasing dividends over time⏳. The company recently increased its share repurchase authorization by $10 billion to a total of $12 billion, providing flexibility, though a modest level of repurchases is expected in 2025 given investment opportunities. The company remains committed to not having excess cash build on its balance sheet.